The Effect of Lactoferrin versus Iron Supplement in Treating Iron Deficiency Anemia and Helping weight Loss in Obese School Age Children

Thesis

Submitted for Partial Fulfillment of Master Degree in Pediatrics

Bv

Asmaa Zaki Sayed Ahmed

MB.B.Ch, (2014)
Faculty of Medicine, Ain Shams University

Supervised By

Prof. Dr. Mohamed Ashraf Abdel El Wahid

Professor of Pediatrics
Faculty of Medicine, Ain Shams University

Prof. Dr. May Fouad Nassar

Professor of Pediatrics
Faculty of Medicine, Ain Shams University

Dr. Marian Girgis Rizk

Lecturer of Pediatrics
Faculty of Medicine, Ain Shams University

Faculty of Medicine
Ain Shams University
2019



First and foremost, I feel always indebted to **ALLAH** the Most Kind and Most Merciful.

I'd like to express my respectful thanks and profound gratitude to **Prof. Dr. Mohamed Ashraf Abdel El Wahid,** Professor of Pediatrics, Faculty of Medicine – Ain Shams University for his keen guidance and kind supervision.

I am also delighted to express my deepest gratitude and thanks to **Prof. Dr. May Fouad Nassar,** Professor of Pediatrics, Faculty of Medicine – Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.

I am deeply thankful to **Dr. Marian Girgis Rizk,** Lecturer of Pediatrics, Faculty of Medicine, Ain Shams University, valuable advices and continuous encouragement, which made the completion of this work possible.

I would like to express my hearty thanks to all **my family** for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Asmaa Zaki



Contents

Title	Page No.
List of Abbreviations	I
List of Tables	
List of Figures	IV
Introduction	1
Aim of the Work	3
Chapter (1): Obesity in Children	4
Chapter (2): Iron Deficiency Anemia in	Children19
Chapter (3): Relation between Obesity	and Iron
Deficiency Anemia	27
Chapter (4): Lactoferrin versus Ferrous	s in the
Treatment of Iron Deficiency Anemia i	n Obese
Children	31
Subject and Methods	37
Results	47
Discussion	84
Summary	88
Conclusion	91
Recommendations	92
References	93
Arabic Summary	

List of Abbreviations


Abb.	Full term
BMI	Body mass index
CAD	Coronary artery disease
CNS	Central nervous system
GM-CSF	Granulocyte monocyte colony stimulating factor
Hb	Hemoglobin
HDL	High-density lipoprotein
IDA	Iron deficiency anemia
IL	Interleukin
LF	Lactoferrin
MAOIs	Monoamine oxidase inhibitors
MCH	Mean corpuscular hemoglobin
MCV	Mean corpuscular Volume
NAD	Nicotinamide Adenine Dinucleotide
NAFLD	Nonalcoholic fatty liver disease
NHANES	National Health and Nutrition Examination Survey
PCOS	Polycystic ovary syndrome
TCAs	Tricyclic antidepressants
TIBC	Total Iron Binding Capacity
UIBC	Unsaturated Iron Binding Capacity
US	United States
WHO	World Health Organization

ı

List of Tables

Table	Title	Page
1	Comparison between the two groups as regards age and gender distribution	48
2	Comparison between the initial anthropometric measurements in the iron group and lactoferrin group	50
3	Comparison of the initial 24 hours dietary recall between the iron group and lactoferrin group	51
4	Comparison between the initial hemoglobin, Iron profile and lipid profile in the iron group and lactoferrin group	52
5	Comparison between the anthropometric measurements of the iron group and lactoferrin group after intervention	53
6	Comparison between the iron group and lactoferrin group as regards 24 hours dietary recall of feeding after intervention	56
7	Comparison between the iron group and lactoferrin group after 12 weeks intervention as regards Hemoglobin, MCV, MCH, iron profile and lipid profile	57
8	Comparison between the initial anthropometric measurements and after 12 weeks intervention in the iron group	59
9	Comparison between the initial and after 12 weeks intervention in the iron group regarding of Hemoglobin, iron profile &lipid profile	64

Table	Title	Page
10	Comparison between the initial and after 12 weeks intervention in the lactoferrin group regarding of anthropometric measurements and 24hours dietary recall	68
11	Comparison between the initial hemoglobin, iron profile & lipid profile and after 12 weeks intervention in lactoferrin group	72
12	Comparison the rate of change between the initial and after 12 weeks intervention regarding of the anthropometric measurements and 24hours dietary recall, hemoglobin, iron profile and lipid profile in the iron group and the lactoferrin group	76
13	The relationship between the rate of change in the hemoglobin level and other data of the study after 12 weeks intervention in both groups	80
14	Tell us the prevalence of iron deficiency anemia in the obese children	82
15	Comparisons between side effect of lactoferrin and iron intervention in duration follow up 12 weeks	83



List of Figures

Figure	Title	Page	
1	Relationship between appetite and hunger	9	
	hormones	9	
2	Normal physiology of iron homeostasis	22	
3	Daily recommended amount of iron	24	
4	Association between hepcidin and obesity	29	
5	Structure of lactoferrin	33	
6	Flow chart of the studied cases	48	
7	Comparison between the two groups	49	
	regarding age	47	
8	Comparison between the two groups as	49	
	regards to gender distribution	17	
9	Comparison of BMI-z score & waist/hip		
	ratio between the iron group and	54	
	lactoferrin after 12 weeks intervention		
10	Comparison of Hip circumference & Waist		
	circumference between the iron &	55	
	lactoferrin group after 12weeks		
11	intervention		
11	Comparison of hemoglobin between the	۲o	
	iron group and lactoferrin group after 12 weeks treatment	58	
12			
12	Comparison of anthropometric measurements (Weight, height & BMI)		
	between the initially and after 12weeks	60	
	intervention in the iron group		
13	Comparison of dietary history (water %,		
10	Protein &iron) initially and after 12 weeks	61	
	interventional in the iron group	- -	
14	Comparison between initially and after 12	6.1	
	weeks interventional in the iron group as	61	

Figure	Title	Page
	regards to calories and carbohydrates	
15	Comparison between initially and after 12 weeks interventional in the iron group as regards to calories	62
16	Comparison between the initial anthropometric measurements (BMI-z score& Waist/Hip ratio) and after 12 weeks intervention in the iron group	62
17	Comparison between the initial Waist circumference and Hip circumference and after 12 weeks intervention in the iron group	63
18	Comparison between the initial Fat free mass and after 12 weeks intervention in the iron group	63
19	Comparison between the initial hemoglobin and after 12 weeks intervention in the iron group	65
20	Comparison between the initial serum ferritin and serum iron and after 12 weeks intervention in the iron group	66
21	Comparison between the initial TIBC, Cholesterol and triglyceride and after12weeks intervention in the iron group	66
22	Comparison between the initial of MCV and after 12weeks intervention in the iron group	67
23	Comparison between the initial MCH &	67

Figure	Title	Page
	Transferrin saturation and after 12 weeks	
	intervention in the iron group	
24	Comparison between the initial and after	
	intervention 12 weeks regarding the	69
	Weight, height & BMI in lactoferrin group	
25	Comparison between the initial 24Hours	
	dietary recall (calories /d) and after 12	70
	weeks interventional in lactoferrin group	
26	Comparison between the initial and	
	after12weeks intervention in lactoferrin	70
	group regarding the BMI-z score &	
	waist/hip ratio	
27	Comparison between the initial fat free	74
	mass and after 12weeks intervention in	71
20	lactoferrin group	
28	Comparison between the initial and after	73
29	12weeks intervention in lactoferrin group	
29	Comparison between the initial TIBC and after 12weeks intervention in lactoferrin	74
	group	7 1
30	Comparison between the initial and after	
	12weeks intervention as regard LDL,	74
	Cholesterol, triglyceride level	
31	Comparison between the initial MCV and	
	after 12weeks intervention in lactoferrin	75
	group	
32	Comparison between the initial and after	
	12weeks intervention in lactoferrin group	75
	regarding of MCH & transferrin	75
	saturation%	

≥ List of Tables ₹

Figure	Title	Page
33	Comparison between the initial and after	
	12weeks intervention regarding of water %	77
	in both group	
34	Comparison between the initial MCV and	
	HB and after 12weeks intervention in both	78
	groups	
35	Comparison between the initial MCH and	78
	after 12weeks intervention in both groups	70
36	Comparison between the initial serum	
	ferritin and after 12weeks intervention in	79
	both groups	
37	The prevalence of iron deficiency anemia in	02
	obese children	82

Introduction

Overweight and obese children are at risk for immediate and long-term health consequences, including cardiovascular and metabolic risks as iron deficiency anemia, and additional comorbidities, including obstructive sleep apneas, nonalcoholic fatty liver diseases, and musculoskeletal disorders (*Ebbeling et al.*, 2002).

Low iron status in overweight and obese individuals might also be caused by greater iron requirements because of poor dietary iron intake, dilution because of increased blood volume, and reduced iron absorption because of adiposity-related inflammation or a combination of the three scenarios (*Eckhardt et al.*, 2008).

Lactoferrin (LF) is a non heme iron-binding glycoprotein strongly expressed in human and bovine milk and it plays many functions during infancy such as iron homeostasis and defense against microorganisms. In humans, LF is mainly expressed in mucosal epithelial and immune cells. LF is the second most abundant protein in human milk. It is mainly present in body fluids since it is

found in most mucosal secretions such as saliva, tears, bile, pancreatic juice, intestinal mucus, seminal fluid, and genital secretions (*Lambert*, 2012).

The level of LF concentration in the body is inversely associated with BMI, the (waist / hip) ratio and the fasting TAG and glucose concentrations, and positively with insulin sensitivity. Also, preservation of LF leads to decreased free lipopolysaccharide concentration and maintenance of an adequate lipid profile (Moreno et al., 2010).

Aim of the Work

- 1- Determining the prevalence of iron deficiency anemia in obese school age children.
- 2- Studying the effect of lactoferrin versus iron supplementation on treatment of iron deficiency anemia in obese school age children.
- 3- Studying the effect of lactoferrin versus iron supplementation on weight loss in obese school age children.

Chapter (1):

Obesity in Children

Introduction

Childhood obesity is one of the most serious public health challenges of the 21st century. The problem is global and is steadily affecting many low- and middle-income countries, particularly in urban settings. The prevalence has increased recently at an alarming rate (WHO, 2019).

The rise in the rate of obesity in school-aged children, adolescents, and young adults in the last 30 years is a clear healthcare crisis that needs to be addressed (*Karp & Gesell, 2015*).

Obesity in children is a complex disorder. Its prevalence has increased significantly in recent years that many consider it as a major health concern of the developed world. The National Health and Nutrition Examination Survey (NHANES) indicates that the prevalence of obesity is increasing in all pediatric age groups, in both sexes, and in various ethnic and racial groups (Skinner et al., 2015).

Definitions:

Overweight and obesity are defined as "abnormal or excessive fat accumulation that presents a risk to health. It is difficult to develop one simple index for the measurement of overweight and obesity in children and adolescents because their bodies undergo a number of physiological changes as they grow (WHO, 2019).

Epidemiology:

i. International statistics

International data regarding childhood obesity varies, and accuracy may be less than optimal; however, the highest rates for children at risk for obesity were found in Malta (25.4%) and the United States (25.1%). Lithuania (5.1%) and Latvia (5.9%) had the lowest rates (Ogden et al., 2015).

ii. United States statistics

The prevalence of obesity in children and adolescents in 2009-2010 was noted to be 16.9% which is comparable to the prevalence rates reported in 2007-2008 (*Peirson et al.*, 2015).